Highlights From The Movement Disorders Society Virtual Congress 2020

Every year the International Parkinson and Movement Disorder Society (MDS) holds a conference and every year APDA is there, learning about the newest research and sharing our resources with the wider PD community. The MDS Congress is the preeminent gathering of medical professionals from around the world who are dedicated to Parkinson’s disease (PD) and other movement disorders.  So much fascinating information is shared at the Congress that each year we report back to our readers about what we have learned. You can read our recaps from 2018 and 2019 to learn more.
This year the world has been turned upside down due to the COVID-19 pandemic, and an international conference that typically brings together thousands of people from dozens of countries around the world, was not possible. And much like many other in-person gatherings, this one went virtual.  It was a great accomplishment to conduct such a massive meeting on a virtual platform, and it was very exciting to be a participant in that inaugural event.
The event consisted of scientific talks as well as abstracts, or brief reports of new research.
Highlights from the Research Presented
Here are my highlights from the research abstracts presented at the first-ever MDS Virtual Congress 2020 along with a comment about why each project is important. It was interesting to see several COVID-19-related research projects presented.
Neurological manifestations of COVID-19 in Parkinson’s disease (Agarwal, P. et al)
The abstract reported neurologic manifestations in seven patients with Parkinson’s disease (PD) and COVID-19. Among this cohort, it was common to present with neurologic symptoms such as increased confusion. One patient presented with falls and worsening of tremor, which was initially attributed to progression of PD. Two of the patients died and five recovered to their baseline.
Take home message: It is important to recognize neurological manifestations of COVID-19 in PD patients in order to correctly identify and treat COVID-19 in this population. (Learn more about research related to the intersection of PD and COVID-19.)
Utility of deep brain stimulation remote programming for Parkinson’s disease during the COVID-19 outbreak (Zhang C. et al)
SceneRay, a medical device company based in China developed a deep brain stimulation (DBS) system that enables remote programming. The system allows the physician to change the DBS parameters of an individual’s device from a remote location. This technology is not available yet in the US. This abstract described the experience of practitioners using this technology in six centers in China both before and during the COVID-19 pandemic.
Take home message: Physician adjustment of DBS parameters remotely is available in some parts of the world (and hopefully will be available in the US in the future). Because of its convenience, it can be very helpful for patients who might have trouble getting to the doctor in person, especially during the COVID-19 pandemic.
UCB0599 transition to the clinic: An orally available brain-penetrant inhibitor of alpha-synuclein misfolding in Phase I development for Parkinson’s disease (Smit JW at al)
As explained in a recent blog, targeting of misfolded alpha-synuclein is one of the prime targets for

Content provided by the American Parkinson Disease Association

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *